Minocycline Hydrochloride · Regulatory label update

FDA supplemental approval: Minocycline Hydrochloride (Labeling)

U.S. Food and Drug Administration · May 12, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental labeling change for minocycline hydrochloride 50 mg capsules on 12 May 2026. This regulatory action record does not contain clinical trial results, efficacy data, or comparative safety information; it documents only a labeling submission and its approval status.

What was studied

Regulatory label update.

Key findings

Safety

This record does not contain clinical trial results, efficacy data, or safety outcomes. No comparative efficacy, adverse event rates, or population studied data are reported.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval for minocycline hydrochloride labeling; records a regulatory action, not a clinical trial or efficacy finding.

Reported figures

Quoted from the source exactly as published.

Approval status date2026-05-12

FormulationMINOCYCLINE HYDROCHLORIDE, CAPSULE, ORAL, 50 MG BASE

Caveats

This record does not contain clinical trial results, efficacy data, or safety outcomes.
The nature and content of the labeling changes are not specified.
No comparative efficacy, adverse event rates, or population studied data are reported.
Approval of a labeling supplement does not imply clinical superiority or new evidence.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Not applicable; this is a regulatory action, not a clinical study.

Directness

insufficient

No clinical outcome data reported in this regulatory record.

Consistency

insufficient

No comparison or efficacy data provided; labeling supplement only.

Risk of bias

insufficient

Not applicable to regulatory labeling approval record.

Sample adequacy

insufficient

No study population or sample size data in this record.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA063181. This is a regulatory action record, not a clinical study. Brand name: MINOCYCLINE HYDROCHLORIDE. Active ingredient: MINOCYCLINE HYDROCHLORIDE. Sponsor: WATSON LABS TEVA. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-05-12. Products: MINOCYCLINE HYDROCHLORIDE, CAPSULE, ORAL, MINOCYCLINE HYDROCHLORIDE EQ 50MG BASE.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Watson Labs TevaMinocycline Hydrochloride